|
|
Article: CryoLife(R) Announces Results of Aurazyme(R)'S Pre-Clinical Animal Trials of AZ-CINN 310 to Treat Breast Cancer.
- Article from:
- PR Newswire
- Article date:
- September 9, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CryoLife, Inc.'s , subsidiary, Aurazyme Pharmaceuticals, Inc., announced today that in pre- clinical animal trials AZ-CINN-310 demonstrated accelerated destruction of breast cancer tumor cells at the site of activation with a single low dose of paclitaxel when AZ-CINN 310 was light activated. AZ-CINN 310 links paclitaxel, a drug used in chemotherapy, to Herceptin, an antibody that targets HER-2 antigens that are above normal in certain breast cancer patients. The study involved the implantation and growth of human breast cancer cells in mice.
The pre-clinical studies were performed by Dr. Mark Pegram at UCLA's Jonsson Comprehensive Cancer Center and were funded ...